Buy One Get One free -Llimited Time Offer X
Olmetrack H 12.5 Mg/40 Mg Tablet is a prescription drug, available for use as Tablet. The alternative uses of Olmetrack H 12.5 Mg/40 Mg Tablet have also been explained below.
Medical history of the patient along with age and gender determines the dosage of Olmetrack H 12.5 Mg/40 Mg Tablet. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Refer to the dosage section for a detailed discussion.
Olmetrack H 12.5 Mg/40 Mg Tablet also has some side effects, the most common being Upper respiratory tract infection. While these are the most often observed Olmetrack H 12.5 Mg/40 Mg Tablet side effects, there are can be others also. These have been listed below. Such side effects of Olmetrack H 12.5 Mg/40 Mg Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Olmetrack H 12.5 Mg/40 Mg Tablet's effect during pregnancy is Severe and Mild while nursing. In addition, Olmetrack H 12.5 Mg/40 Mg Tablet's effects on the liver, heart and kidney are discussed below in the Olmetrack H 12.5 Mg/40 Mg Tablet related warnings section.
Olmetrack H 12.5 Mg/40 Mg Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Asthma, Allergy, Kidney Disease are examples of such conditions. Some other conditions that can be affected by Olmetrack H 12.5 Mg/40 Mg Tablet are listed in the contraindications section below.
Besides this, Olmetrack H 12.5 Mg/40 Mg Tablet may also have severe interaction with some medicines. A complete list of these interactions is given below.
You should also be aware that Olmetrack H 12.5 Mg/40 Mg Tablet is not safe while driving, and is not addiction.
Olmetrack H 12.5 Mg/40 Mg Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Olmetrack H 12.5 Mg/40 Mg Tablet safe for pregnant women?
Pregnant women may get severe side effects after taking Olmetrack H. If you are pregnant, do not take Olmetrack H without a doctor's advice.
Is the use of Olmetrack H 12.5 Mg/40 Mg Tablet safe during breastfeeding?
Olmetrack H may have very limited harmful effects for breastfeeding women.
What is the effect of Olmetrack H 12.5 Mg/40 Mg Tablet on the Kidneys?
Very few cases of side effects of Olmetrack H on kidney have been reported.
What is the effect of Olmetrack H 12.5 Mg/40 Mg Tablet on the Liver?
Very few cases of side effects of Olmetrack H on the liver have been reported.
What is the effect of Olmetrack H 12.5 Mg/40 Mg Tablet on the Heart?
Very few cases of side effects of Olmetrack H on the heart have been reported.
If you are suffering from any of the following diseases, you should not take Olmetrack H 12.5 Mg/40 Mg Tablet unless your doctor advises you to do so -
Is this Olmetrack H 12.5 Mg/40 Mg Tablet habit forming or addictive?
No, there is no any evidence that Olmetrack H 12.5 Mg/40 Mg Tablet is addictive.
Interaction between Food and Olmetrack H 12.5 Mg/40 Mg Tablet
Taking Olmetrack H 12.5 Mg/40 Mg Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Olmetrack H 12.5 Mg/40 Mg Tablet
Consult your doctor before consuming alcohol while taking Olmetrack H 12.5 Mg/40 Mg Tablet as it can have severe side effects.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Hydrochlorothiazide
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 582-586
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 446-448
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Benicar (olmesartan medoxomil)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173